(Q51103584)

29 March 2018

editorial

0 references

title

Naturally acquired immunity against human papillomavirus (HPV): why it matters in the HPV vaccine era. (English)

1 reference

29 March 2018

1 reference

Silvia Franceschi

1

0 references

author name string

Iacopo Baussano

series ordinal

2

1 reference

29 March 2018

language of work or name

English

0 references

publication date

8 March 2014

1 reference

29 March 2018

Journal of Infectious Diseases

number of pages

3

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

29 March 2018

volume

210

1 reference

29 March 2018

issue

4

1 reference

29 March 2018

page(s)

507-509

1 reference

29 March 2018

Immune evasion in human papillomavirus-associated cervical cancer

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

The use of human papillomavirus seroepidemiology to inform vaccine policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Model for assessing human papillomavirus vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Modelling patterns of clearance of HPV-16 infection and vaccination efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Evaluating human papillomavirus vaccination programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Type-specific human papillomavirus biological features: validated model-based estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Inference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

HPV-16 infection and cervical cancer: modeling the influence of duration of infection and precancerous lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Infection transmission and chronic disease models in the study of infection-associated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU143

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIU143

1 reference

29 March 2018

1 reference

29 March 2018